Biontech Se

Genmab A+s

Ganmab A/s

Lars Guelen

Ugur Sahin

Sina Fellermeier-kopf

Janine Schuurman

Aran Frank Labrijn

Alexander Muik

Esther Cornelia Wilhelmina Breij

Bart-Jan De Kreuk

Richard Hibbert

David Satijn

Friederike Gieseke

Joost J Neijssen

Esther C W Breij

Dennis Verzijl

Kristel Kemper

David P E Satijn

Ivan Kuzmanov

Patricia Garrido Castro

Jordan Blum

Andreea Ioan

Maarten Van Der Kroef

Maren Köhne

Pauline Linda De Goeje

Andrea Gorlani

Karsten Beckmann

Kristina Nürmberger

Claudia Paulmann

The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Antibodies capable of binding to OX40, variants thereof and uses thereof

The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.

Binding agents binding to EpCAM and CD137

The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

Growing community of inventors

Utrecht, Netherlands

Lars Guelen